Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 12/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ACLY | P53396 | 2/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7572525 | 0.78 | CCR2 (0.63) | CCR2POLB | |
| SCHEMBL15009769 | 0.73 | ACLY (0.47) | ACLY | |
| SCHEMBL9933360 | 0.72 | CCR2 (1.00) | CCR2 | |
| SCHEMBL15009570 | 0.71 | NPC1 (0.53) | ACLYSLC40A1 | |
| SCHEMBL15009254 | 0.71 | TP53 (0.50) | — | |
| SCHEMBL8113005 | 0.70 | POLB (0.51) | CCR2POLBPIK3CD | |
| SCHEMBL15009678 | 0.70 | MAPT (0.51) | CCR2 | |
| SCHEMBL15009116 | 0.70 | PGR (0.56) | SLC40A1 | |
| SCHEMBL9934423 | 0.69 | CCR2 (0.88) | CCR2 | |
| SCHEMBL3748809 | 0.69 | CCR2 (0.67) | CCR2ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098309-A1 | METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS | ACUMEN PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | claimed |
| EP-2194975-A2 | METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS | Acumen Pharmaceuticals, Inc. (US) | 2010-06-16 | — | — | EP | claimed |
| WO-2009009768-A2 | METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS | ACUMEN PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | WO | claimed |
| US-20110098309-A1 | METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS | ACUMEN PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| EP-2194975-A2 | METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS | Acumen Pharmaceuticals, Inc. (US) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009009768-A2 | METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS | ACUMEN PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098309-A1 | METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS | APP, APBA1, BACE1 | CCR2 2698/4885POLB 4100/4885ACLY 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.